Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutes-Reference-Cited by-同舟云学术

Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutes

Published:2020-05-11 Issue:8 Volume:25 Page:1543-1550
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Numakura Kazuyuki^ORCID,Kobayashi Mizuki,Hatakeyama Shingo,Naito Sei,Horikawa Yohei,Tanaka Toshikazu,Kamada Sachiko,Muto Yumina,Yamamoto Ryohei,Koizumi Atsushi,Nara Taketoshi,Kanda Sohei,Saito Mitsuru,Narita Shintaro,Inoue Takamitsu,Shimoda Naotake,Tsuchiya Norihiko,Ohyama Chikara,Habuchi Tomonori

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-020-01693-y.pdf

Reference28 articles.

1. Thompson RH, Ordonez MA, Iasonos A et al (2008) Renal cell carcinoma in young and old patients—is there a difference? J Urol 180(4):1262–1266. https://doi.org/10.1016/j.juro.2008.06.037(discussion 1266, PMID: 18707708 PMCID: PMC2615196)

2. Konishi S, Hatakeyama S, Tanaka T et al (2018) Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis. Med Oncol 36(1):6. https://doi.org/10.1007/s12032-018-1231-3(PMID: 30474747)

3. Harada K, Nozawa M, Uemura M et al (2019) Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan. Int J Urol 26(2):202–210. https://doi.org/10.1111/iju.13830(PMID: 30345560)

4. Tsuchiya N (2019) Molecular-targeted therapy in advanced renal cell carcinoma based on pharmacokinetics, pharmacodynamics and pharmacogenetics: a proposed strategy. Int J Urol 26(1):48–56. https://doi.org/10.1111/iju.13805(PMID: 30276868)

5. Konishi S, Hatakeyama S, Numakura K et al (2019) Validation of the IMDC prognostic model in patients with metastatic renal-cell carcinoma treated with first-line axitinib: a multicenter retrospective study. Clin Genitourin Cancer 17(5):e1080–e1089. https://doi.org/10.1016/j.clgc.2019.07.006(PMID: 31416753)

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study;European Journal of Cancer;2024-04

2. Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma;Cancer Medicine;2023-07-05

3. Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: A systematic review and meta‐analysis;European Journal of Clinical Investigation;2022-07-21

4. Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism;Genes;2022-07-05

5. Real-World Experience with Nivolumab in Metastatic Renal Cell Carcinoma Patients Who Have Progressed on Prior Therapies: A Single-Center Study from India;South Asian Journal of Cancer;2022-02-11